The primary focus of drug development for AD has been on directly targeting its two key pathological features: the aggregation of beta-amyloid plaques (Aβ) and the formation of tau tangles, also known as tau neurofibrillary tangles (NFTs). Here, MAPT is linked to Alzheimer disease.